AVS Pulse

About AVS Pulse

AVS is an early-stage medical device company focused on revolutionizing the treatment of severely calcified arterial disease. Operating in the medical technology sector, AVS serves healthcare providers and patients who require advanced interventional therapies. The company has developed the PULSE System, a novel device that uses a pulsatile mechanism to shatter calcium deposits and expand blood vessels, all within a single, minimally invasive procedure. This technology aims to improve outcomes for patients with peripheral artery disease (PAD) by offering a safer and more effective alternative to current treatments.

Founded in 2017 by a team of clinicians and engineers from the University of Michigan, AVS has made significant strides in its development journey. The company has received grant support from the NIH, Cleveland Clinic, and U of M Fast Forward Medical Innovation. By 2019, AVS had completed successful animal studies and early cadaver studies, leading to the filing of patents with the US Patents Trademark Office. In 2020, the company secured funding from a visionary healthcare investment firm and hired a management team to drive its mission forward.

AVS operates on a business model that focuses on research and development, clinical trials, and eventual commercialization of its PULSE System. Revenue will be generated through the sale of the device to hospitals and clinics, as well as potential licensing agreements and partnerships with larger medical device companies.